ViroXis Gets $2.5M From TETF

San Antonio-based ViroXis, a developer of an anti-viral biopharmaceutical derived from sandalwood oil, has raised $2.5M in an investment round, according to Startech and the South Texas Regional Center of Innovation and Commercialization. The funding came from the Texas Emerging Technology Fund (TETF). The firm's lead compound is targeted at the treatment of Human Papillomavirus (HPV), the virus that causes skin warts. More information »